Avidity Biosciences マネジメント

マネジメント基準チェック /24

Avidity Biosciencesの CEO はSarah Boyceで、 Oct2019年に任命され、の在任期間は 5.08年です。の年間総報酬は$ 11.14Mで、 5.7%給与と94.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.06%を直接所有しており、その価値は$ 3.04M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と5.2年です。

主要情報

Sarah Boyce

最高経営責任者

US$11.1m

報酬総額

CEO給与比率	5.7%
CEO在任期間	5.1yrs
CEOの所有権	0.06%
経営陣の平均在職期間	3.8yrs
取締役会の平均在任期間	5.2yrs

経営陣の近況

Recent updates

Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term

Oct 02

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Aug 16

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Aug 14

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Mar 01

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Nov 04

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Apr 08

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Nov 17

Avidity slips 20% as FDA places lead asset on partial clinical hold

Sep 27

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Jul 29

Avidity stock rises amid Chardan starting coverage with Buy

Jul 20

Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides

Jul 12

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Mar 26

Avidity Biosciences: Risks And Potential

Dec 09

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Nov 30

CEO報酬分析

Avidity Biosciences の収益と比較して、Sarah Boyce の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$280m
Jun 30 2024	n/a	n/a	-US$252m
Mar 31 2024	n/a	n/a	-US$229m
Dec 31 2023	US$11m	US$635k	-US$212m
Sep 30 2023	n/a	n/a	-US$202m
Jun 30 2023	n/a	n/a	-US$193m
Mar 31 2023	n/a	n/a	-US$192m
Dec 31 2022	US$5m	US$601k	-US$174m
Sep 30 2022	n/a	n/a	-US$162m
Jun 30 2022	n/a	n/a	-US$148m
Mar 31 2022	n/a	n/a	-US$128m
Dec 31 2021	US$6m	US$570k	-US$118m
Sep 30 2021	n/a	n/a	-US$96m
Jun 30 2021	n/a	n/a	-US$78m
Mar 31 2021	n/a	n/a	-US$62m
Dec 31 2020	US$823k	US$484k	-US$44m
Sep 30 2020	n/a	n/a	-US$38m
Jun 30 2020	n/a	n/a	-US$34m
Mar 31 2020	n/a	n/a	-US$28m
Dec 31 2019	US$4m	US$104k	-US$25m

報酬と市場: Sarahの総報酬 ($USD 11.14M ) は、 US市場 ($USD 7.91M ) の同規模の企業の平均を上回っています。

報酬と収益: Sarahの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Sarah Boyce (52 yo)

5.1yrs

在職期間

US$11,139,719

報酬

Ms. Sarah Boyce is Director of Abcuro, Inc. from July 2024. She serves as Independent Director of Contineum Therapeutics, Inc Since June 2024. She has been President, Chief Executive Officer and Director a...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Troy Wilson	Co-Founder & Independent Chairman	12yrs	US$260.31k	0.064% $ 3.2m
Sarah Boyce	President	5.1yrs	US$11.14m	0.060% $ 3.0m
Michael MacLean	Chief Financial & Chief Business Officer	4.5yrs	US$4.48m	0.0065% $ 325.6k
W. Michael Flanagan	Chief Scientific & Technical Officer	3.8yrs	US$4.89m	0.072% $ 3.6m
Teresa McCarthy	Chief Human Resources Officer	4.3yrs	US$3.73m	0.079% $ 4.0m
Arthur Levin	Distinguished Scientist	1.8yrs	US$3.03m	0.13% $ 6.5m
Eric Mosbrooker	Chief Strategy Officer	less than a year	US$235.31k	0% $ 0
Mark Davis	Scientific Founder	12.8yrs	データなし	データなし
Frank McCormick	Scientific Founder & Member of Scientific Advisory Board	12.8yrs	データなし	データなし
John Moriarty	Chief Legal Officer & Corporate Secretary	less than a year	データなし	データなし
John Wallen	Consultant	less than a year	データなし	データなし
Kathleen Gallagher	Chief Program Officer	1.8yrs	データなし	データなし

3.8yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: RNAの経営陣は経験豊富であると考えられます ( 3.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Troy Wilson	Co-Founder & Independent Chairman	12yrs	US$260.31k	0.064% $ 3.2m
Sarah Boyce	President	5.1yrs	US$11.14m	0.060% $ 3.0m
Arthur Levin	Distinguished Scientist	1.8yrs	US$3.03m	0.13% $ 6.5m
Mark Davis	Scientific Founder	no data	データなし	データなし
Frank McCormick	Scientific Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Carsten Boess	Independent Director	4.6yrs	US$245.31k	0% $ 0
Richard Heyman	Member of Scientific Advisory Board	no data	データなし	データなし
Edward Kaye	Independent Director	5.3yrs	US$244.31k	0% $ 0
Eran Nadav	Observer	no data	データなし	データなし
Christopher Kirk	Member of Scientific Advisory Board	no data	データなし	データなし
Noreen Henig	Independent Director	5.3yrs	US$245.81k	0% $ 0
Ryan Corcoran	Member of Scientific Advisory Board	no data	データなし	データなし

5.2yrs

平均在職期間

58.5yo

平均年齢

経験豊富なボード: RNAの取締役会は経験豊富であると考えられます ( 5.2年の平均在任期間)。

Avidity Biosciences マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Avidity Biosciences, Inc. Announces Executive Changes

Avidity Biosciences, Inc. Appoints Simona Skerjanec as Board of Directors

Director recently sold US$542k worth of stock

President notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$224k worth of stock

President notifies of intention to sell stock

Recent updates

Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophin Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44 Trial

Avidity Biosciences, Inc. Announces Executive Changes

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $400.9 million.

Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

Avidity Biosciences, Inc. Appoints Simona Skerjanec as Board of Directors

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1

New minor risk - Insider selling

Director recently sold US$542k worth of stock

Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding

Consensus revenue estimates increase by 140%

Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor™ Trial

President notifies of intention to sell stock

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Full year 2023 earnings: EPS and revenues miss analyst expectations

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping

Avidity Biosciences, Inc. Plans to Initiate the Global Phase 3 Harbour Trial of AOC 1001 for Adults Living with Myotonic Dystrophy Type 1, in Mid-2024

Avidity Biosciences Reports Positive Data Demonstrating Aoc 1044 Delivers Unprecedented Concentrations of Pmo in Muscle Following A Single Dose in Healthy Volunteers from Phase 1/2 Explore44™ Trial for Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 104%

Avidity Biosciences, Inc. announced that it expects to receive $39.999993 million in funding from Bristol-Myers Squibb Company

Consensus revenue estimates increase by 17%

Price target increased by 10% to US$40.80

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Avidity Biosciences, Inc. Presents New Data Regarding Its Clinical Study of AOC 1001 for Adults with Myotonic Dystrophy Type 1

Price target increased by 10% to US$40.80

Consensus revenue estimates increase by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Provides an Update to the Status of the Partial Clinical Hold Related to Its AOC 1001 Product Candidate

Consensus revenue estimates increase by 11%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Price target decreased by 7.8% to US$40.57

Full year 2022 earnings released: US$3.34 loss per share (vs US$2.85 loss in FY 2021)

Chief Scientific Officer exercised options and sold US$224k worth of stock

Avidity Biosciences, Inc. Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

President notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$208k worth of stock

Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

Chief Scientific Officer exercised options and sold US$831k worth of stock

Price target increased to US$44.00

Avidity Biosciences, Inc. Announces Positive AOC 1001 Phase 1/2 Marina(Tm) Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Announces Planned Explore44 Trial of AOC 1044 in Healthy Volunteers and Participants with Duchenne Muscular Dystrophy

Avidity Biosciences, Inc. Announces Phase 1/2 EXPLORE44 Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping

Avidity Biosciences Announces the Phase 1/2 Fortitude(Tm) Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences, Inc. Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial

Avidity slips 20% as FDA places lead asset on partial clinical hold

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Avidity Biosciences, Inc. Enrolls Patients in the Marina(Tm) Open-Label Extension Study

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Avidity stock rises amid Chardan starting coverage with Buy

Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides

Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 2000 Growth Index

Avidity Biosciences, Inc. Supports World Facioscapulohumeral Muscular Dystrophy Day and Presents Preclinical Data from FSHD Program

マネジメント基準チェック /24